Malignant melanoma patients with tumor samples with an IHC score > 8 for Anti-CD271, >8 for Anti-GLDC, and >9 for Anti-ERRFI1 are more likely to die early and therefore show a poorer prognosis after diagnosis stage IV in comparison with patients with smaller IHC scores for the described antibodies. The gene discussed is ERRFI1; the disease is neoplasm.